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Abstract
In the present review, we describe here experimental comparative and beneficial effects of 
botulinum neurotoxin A (ANTX) between subtypes A1 and A2 in the pathology of move-
ment disorders, particularly rat Parkinson’s disease model. We and other laboratories have 
shown the beneficial effects, and this novel strategy for intractable brain disorders might 
confer potent and safety therapy in bedside. First, we show the characteristics of ANTXs in 
the genetic aspects of these subtypes, and our intriguing findings of immunological profiles 
in the subtypes between A1NTX and A2NTX. Then, we state the distinct diffusion in the 
body between A1NTX and A2NTX. Importantly, we describe that the intra-brain treat-
ment of small animals with A2NTX subtype results in improvements of pathologies more 
effectively and provides greater safety than those of A1NTX in a rat 6-OHDA Parkinson’s 
disease (PD) model. Finally, we represent that the different efficacies between ANTXs are 
likely due to each localization in the brain; A2NTX is strictly limited in the injected regions, 
while A1NTX diffused other brain regions. Thus, therapeutic avenue using A2NTX in 
incurable PD including other movement disorders could be a druggable target in the future.
Keywords: botulinum neurotoxin type A, pharmacokinetics/pharmacodynamics, 
Parkinson’s disease, therapeutics, safety, experimental, rats
1. Introduction
Clostridium botulinum produces highly potent neurotoxin, which causes a persistent paralysis 
of peripheral nerve terminals. The toxin is classified into seven serotypes (A–G). Type A, 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
B, E, and F toxins are responsible for human botulism, whereas type C and D toxins cause 
botulism in other animals. The toxins are large complexes, known as progenitor toxins, which 
differ in terms of molecular size. The progenitor toxins are containing a neurotoxin (NTX) and 
several nontoxic components. The nontoxic proteins compose a nontoxic non-hemagglutinin 
component (NTNHA) and several hemagglutinin (HA) component proteins. In botulinum 
complex, the proteins are not covalently linked, but their association occurs in culture. The 
sizes of complex toxins differ, from 900 kDa (LL toxin for type A) to 500 kDa (L toxin for types 
A, B, C, D, and G), down to 300 kDa (M toxin for types A, B, C, D, E, and F). The LL toxin is a 
dimer of L toxin, which consists of NTX, NTNHA, and HAs. The M toxin consists of NTX and 
NTNHA. The complex toxin is also stable at acidic pH but dissociates at alkaline pH (pH ≧ 7).
NTXs are released from C. botulinum as single polypeptides with molecular mass about 
150 kDa, which are proteolytically activated and composed of light chain (50 kDa) and heavy 
chain (100 kDa) by disulfide bond. The light chain (LC) acts as a zinc-dependent endopepti-
dase. The heavy chain is divided into two different functional domains: the amino-terminal 
(H
N
) domain and the carboxyl-terminal (HC) domain. The HC acts as the receptor-binding domain, and H
N
 acts as pH-dependent translocation domain of LC from endosome to cyto-
sol. Neuronal endocytosis is driven by the formation of protein complex between the vesicle 
N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE), VAMP2, and the 
plasma membrane SNAREs, synaptosomal-associated protein of 25 kDa (SNAP-25) and syn-
taxin [1]. Type C toxin cleaves both SNAP25 and syntaxin; type B, D, F, and G toxins only 
target VAMP; and type A and E toxins cleave SNAP25. NTX inhibits endocytosis by the cleav-
age of one of the three proteins. Due to high efficiency and longevity, the toxins are the most 
widely used therapeutic proteins.
Due to their high efficacy, tolerance, longevity, and safety property, botulinum toxins are the 
most widely used therapeutic proteins. Most of the toxins have several subtypes based on 
amino acid sequence variability. The type A toxins have been subclassified into 10 subtypes 
(A1–A10) [2]. Especially, the toxin products used as treatment for neurologic disorders are 
LL toxin and NTX, produced by botulinum toxin subtype A1. The other subtype of toxins is 
not used clinically, however has been conducted in researches. We have been studying the 
biological characteristic and pharmacology of A2 toxin.
Several species of botulinum neurotoxin are known to act on cholinergic terminals of the periph-
eral neuromuscular junction and the central nervous system (CNS) [3–5]. NTXs cause robust 
inhibition of the voluntary nervous circuits by blocking the release of acetylcholine (ACh) [6]. 
The therapeutic application of A1NTX for neurological disorders such as bradykinesia, urinary 
dysfunction, hemifacial spasm, and cervical dystonia is well established [7]. The type A organ-
isms have been classified into 10 subtypes (A1 to A10) based on the amino acid sequence vari-
ability of NTX [2]. All 10 subtypes bind to presynaptic protein SNAP-25 with similar affinity, 
but A1NTX and A2NTX cleave SNAP-25 more efficiently than that of other subtypes [4, 8, 9].
Recent studies investigated the direct administration of ANTX to the CNS as a therapeutic 
strategy for the treatment of neurological disorders [3–5]. Parkinson’s disease (PD) is charac-
terized by imbalanced cholinergic hyperactivity in the striatum of affected individuals [10, 11]. 
Interruption of ACh release in the striatum by direct injection of BoNT/A has been reported in 
the rat unilateral 6-hydroxydopamine (6-OHDA) model of PD [12].
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This paper will review the recent advance in the genetic, immunological, diffusion in the body 
and experimental animal model of PD in botulinum toxin A.
2. Genetic diversity between A1NTX and A2NTX
2.1. Genetic diversity of gene clusters encoding ANTX complexes
The neurotoxin and nontoxic protein genes are defined as the NTX gene cluster. There are 
two types of nontoxic components of gene organization (HA and Orfx clusters), and C. botu-
linum type A strains were classified according to their harboring of these clusters. The NTX 
genes are encoded by mobile genetic elements that enable horizontal transfer among different 
isolates, which is thought to contribute to evolution of the NTX gene loci and thereby to the 
large number of distinct NTXs that are currently known [13]. Further type A strains have been 
classified as boNT and HA gene cluster typing to be applied for molecular characterization of 
type A strain. Genes encoding components of the A1NTX and A2NTX complex are arranged 
clusters. Type A strains possess HA cluster genes and A1NTX to NTX gene cluster typing 
1, Orfx cluster genes and A2NTX to NTX gene cluster typing 2, and HA cluster genes, Orfx 
cluster genes, and A1NTX with unexpressed or expressed BNTX to NTX gene cluster typing 3 
[14]. Umeda et al. have reported that C. botulinum type A isolates genotypes by combining the 
results of NTX subtype (subtype A1 or A2) gene detection with ha33 and/or p47 gene detec-
tion by multiplex PCR. Ten isolates associated with infant botulism in Japan were divided into 
NTX gene cluster typings 2 and 3 by origin (honey feeding or not) and period (1986–1987 and 
1999–2007). And, four isolates associated with food-borne botulism in Japan were divided 
into NTX gene cluster typings 1 and 3. The multiplex PCR method is easily capable of clas-
sification of NTX gene cluster typing [15]. Further, genetic characterization was performed in 
ten botulism cases in Japan between 2006 and 2011. Except two type B isolates, eight type A 
isolates are NTX gene cluster typings 1 and 3 which are associated with HA cluster genes [16]. 
NTX gene cluster typing 2 is predominant in Europe, while NTX gene cluster typings 1 and 
3 are predominant in the USA [14, 17, 18]. As C. botulinum type A is rarely found in Japanese 
soil, there is a possibility that imported foods are related to botulism cases.
2.2. Immunological differences between A1NTX and A2NTX
The difference in amino acid sequence between subtype A1 and A2 toxins’ light chain is 5%, 
while the difference in heavy chain is 13%. The similarity of heavy chain is lower than light chain. 
These differences appear to indicate that characteristic antigenicity in the heavy chain is more 
conserved than that in the light chain [19]. Differences in antigenicity among subtypes were 
evaluated using monoclonal and polyclonal antibodies [20–23]. Among eight and seven mono-
clonal antibodies against A1NTX and A2NTX, respectively, each of which recognized different 
epitopes, each three specifically reacted with A1NTX and A2NTX. Neutralizing single monoclo-
nal antibodies against A1NTX and A2NTX that recognized LC, H
N
, or HC have been reported, 
respectively (Tables 1 and 2). Each neutralizing antibody mostly neutralized only toxins of their 
own subtypes. It is suggested that the epitopes of neutralizing are present in every domain of 
both subtypes. The 3B10 and 5G2 that are reacting with LC and H
N
, respectively, specifically 
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recognized and neutralized A2NTX. These monoclonal antibodies recognizing epitopes are con-
sidered to function as A2NTX properties. In type B, differences in biological activities among the 
subtypes B1, B2, and B6NTX appeared to be attributable not only to the function in HC but also to the function in H
N
 [24]. For binding of monoclonal antibodies to NTX, KD values of 1F11 for 
A1NTX were 500 hold higher than that for A2NTX and only neutralized A1NTX. However, the 
KD values of 5C7 for A2NTX were 16 hold higher than that for A1NTX did not neutralize both 
NTXs. The neutralization of monoclonal antibody did not correspond to its affinity. And, OD 
values obtained by ELISA did not necessarily correlate with KD values (Table 3).
Type A antitoxin in standard and therapeutic preparation is a polyclonal antibody purified from 
immunized sera with A1NTX; however, there was no report on the reactivity of the standard type 
Table 2. Properties of mAbs raised against A2NTX.
Table 1. Properties of mAbs raised against A1NTX.
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A antitoxin with other subtype toxins. The A1 antitoxin had equivalent potency both the A1NTX 
and A2NTX; however, neutralization titer of A2 antitoxin was 4–9 hold higher against A2NTX 
than against A1NTX. It seems that the difference between the antibody titers against the test 
NTX was due to the standard antitoxin having different reactivities with the NTXs. The binding 
analysis comparing these antitoxins and NTXs by SPR showed that the A1 antitoxin had a higher 
binding affinity and slower dissociation speed with the A1NTX than with the A2NTX. The A2 
antitoxin showed a higher binding affinity than with the A1NTX [22]. Although these NTXs 
show a low level of sequence difference, they have marked a difference in antigenicity, and 
antitoxin preparation should be used for each subtype’s diagnosis and therapy of botulism.
3. Diffusion into the body of botulinum toxins A1 and A2
Botulinum toxins type A have been researched and developed for use as important therapeutic 
agents for neurological disorders such as blepharospasm, hemifacial spasm, various dystonias, 
and overactive bladder [7, 25]. Botulinum toxin type A products, which are used as treatment 
for neurologic disorder, are produced from LL toxin or NTX derived from subtype A1 organ-
isms [26]. The toxins show high-level efficacy at very low doses, but their adverse effects are 
Table 3. Equilibrium dissociation constants (KD)1) of A1NTX and A2NTX with mAbs against A1NTX and A2NTX.
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becoming an issue. In the treatment for torticollis, cervical dystonia, and cosmetic cases, patients 
showed dysphagia or respiratory compromise [27–29]. In clinical studies of treatment for spasm, 
patients who received high-dose toxin showed weakness around the site of administration as 
well as symptoms of botulism [30–32]. The A1 toxins spread to distant regions is considered to 
be due to transport via the body fluid or nerves [33–35]. In addition, A1 toxin was reported to 
transport via a retrograde axonal route in visual nerve and facial motoneurons in rats [3].
The first report of the diffusion of A2 toxin in the body was grip strength study in mice to 
compare with A1 toxin [36]. This study was evaluated by measurement of contralateral grip 
strength as indicator of toxins’ diffusion. The toxins used were A1 L + LL toxin, onabotulinum-
toxinA (A1LL toxin), and A2M toxin and were injected into one side of the gastrocnemius 
muscle, and grip strength of the contralateral hind leg was measured. The study evaluated 
that the doses causing a 20% reduction in the grip strength before injection were calculated 
and these values were termed the 20% toxic doses (TD20). The TD20 of A1L + LL toxin, A1LL toxin, and A2M toxin were 17.0, 16.2, and 37.3 U/kg, respectively. The grip strength test was 
conducted for change in toxins’ forms, measurement sites, and animal species [37]. The grip 
strength test using rats’ forelegs was conducted using A1 neurotoxin (A1NTX), A1LL toxin, 
and A2NTX (Figure 1). The study evaluated that 50% toxic doses (TD50), which caused a 50% 
Figure 1. Time-course of the grip strength of the contralateral foreleg after toxin injection. Rats received A1LLtoxin, 
A1NTX, or A2NTX injection in the left foreleg (each at ○: 1 U, ●: 4 U, △: 8 U, ▲: 12 U, □: 16 U, ■: 20 U, and ◇: 24 U). 
The grip strength was measured in the right foreleg of each rat at 0 (before administration), 1, 2, 3, 4, 7, and 14 days after 
injection. Each point is the mean ± S.E.M. (n = 5). These data are cited from Toxicon (Trii, et al., Vol; 57(1), [2011] pp. 97) 
with the permissions of ELSEVIER.
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reduction in the grip strength before injection, were calculated. The TD50 values of A1NTX, A1LL toxin, and A2NTX were 7.54, 6.35, and 15.62 U/head, respectively. These results indi-
cated that A2NTX required higher dosage than A1 toxins to relax on the contralateral muscle 
and suggested that A1 and A2 toxins have different diffusions in the body.
Why do these toxins make a difference in diffusion in the body? The pathway of A1 and A2 
toxins was physiologically investigated in the immunohistological study [38].
Figure 2. Appearance of botulinum toxin type A-cleaved SNAP-25 (cSNAP-25) in the spinal cord after intramuscular injection 
of A1- and A2NTX. Densitometric analysis on the spinal ventral horns stained for cSNAP-25. A, B: Immunohistochemical 
detection of cSNAP-25 was carried out in the spinal cord 4 days after unilateral injection of A1- or A2-NTX (10 U) into the 
left gastrocnemius muscle. (A: A1NTX, B: A2NTX) 1, 2: Displayed are multiple transverse spinal cord sections stained 
for cSNAP-25 in the toxin treated rats (1) and their graded color-converted images (2), in which labeling intensity is 
indicated in a standard pseudocolor scale from blue (lowest level) through green, yellow, red, and white (highest level). 
3,4: Photomicrographs of the ventral horns stained for cSNAP-25 ipsilateral (3) and contralateral (4) to peripheral toxin 
injection. Scale bars = 200 mm. C: Densitometric analysis on the spinal ventral horns stained for cSNAP-25. 1: The scheme 
shows the transverse spinal cord section at the L5 segment, in which measured areas in the bilateral ventral horn are 
indicated by dashed open boxes colored in red. 2: Optical densities of the ventral horns stained for cSNAP-25 in rats treated 
with saline (n = 3), A1NTX (A1) (n = 6), or A2NTX (A2) (n = 6). For each animal, measurements were made in the ventral 
horns of three spinal cord sections ipsilateral and contralateral to the toxin-injected sites. Values are means ± SD. *P < 0.05, 
A1 versus A2; Mann–Whitney U-test. These data are cited from frontier in neurology (Torii, et al., [2014] pp. 97. 2014; 5:98) 
with permissions of frontier media.
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Figure 3. Possible mechanisms for the central actions of intramuscularly injected botulinum toxin type A in the spinal 
cord. Following unilateral intramuscular A1NTX (A) or A2NTX (B) injection, the catalytically active toxin can be axonally 
transported to the spinal cord through motor and sensory nerves. Subsequently, the toxin can spread throughout the 
gray matter of the spinal cord, including the bilateral ventral and dorsal horns, via a transcytosis (cell-to-cell trafficking) 
mechanism by which a ligand penetrates the neuron at one side, followed by its movement and release at the opposite 
end, with possible up take by second-order neurons. Differential delivery routes by which injected A1NTX and A2NTX 
affect contralateral muscles have also been proposed as A1NTX (A) is transported almost equally to the contralateral 
muscles via this neural pathway and the blood circulation, while A2NTX (B) is mainly transported to contralateral 
muscles via the bloodstream only at higher doses. These data are cited from frontier in neurology (Torii, et al., [2014] 
pp. 5:98) with permissions of frontier media.
Spinal cords (bilateral ventral and dorsal horns), in which A1NTX and A2NTX were injected 
into the gastrocnemius muscle, were strained using botulinum toxin type A-cleaved SNAP-
25 (cSNAP-25). The L5 nerve dominantly innervates the gastrocnemius muscle. The A1NTX 
was observed to have a strong immunoreactivity for cSNAP-25 in the ventral and dorsal 
horns of the spinal cord not only at the segmental level of L5 ipsilateral to the peripheral 
toxin injection site but also to a lesser extent on the contralateral side (Figure 2A). The A2NTX 
was observed to have a strong immunoreactivity at the L5 spinal segment ipsilateral side as 
A1NTX but to a lesser extent on the contralateral side than A1NTX (Figure 2B). In addition, 
the ventral horns stained for cSNAP-25 at the L5 spinal segment in the toxin-treated rats 
were compared by optical density measurements. In both the ipsilateral and contralateral 
ventral horns, cSNAP-25 labeling in rats injected with A1NTX was spread wider than with 
A2NTX (Figure 2C).
The diffusion of A2NTX in the body summarized the previous reports as follows (Figure 3). 
After unilateral intramuscular toxin injection, the catalytically active toxin can be axonally 
transported to the spinal cord through motor and sensory nerves. Subsequently, the toxin can 
spread throughout the gray matter of the spinal cord, including the bilateral ventral and dor-
sal horns, via a transcytosis (cell-to-cell trafficking) mechanism by which a ligand penetrates 
the neuron at one side, followed by its movement and release at the opposite end, with pos-
sible uptake by second-order neurons. Differential delivery routes by which injected A1NTX 
and A2NTX affect contralateral muscles have also been proposed as A1NTX is transported 
almost equally to the contralateral muscles via this neural pathway and the blood circula-
tion, while A2NTX is mainly transported to contralateral muscles via the bloodstream only 
at higher doses.
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4. Therapeutic application of botulinum toxins A1 and A2 in 
Parkinson’s disease
Parkinson’s disease (PD) is one of the most common movement disorders and is characterized 
by a progressive degeneration of nigrostriatal dopaminergic signaling, which leads to the 
unbalanced release of acetylcholine in the striatum [10]. The disturbance of these neuronal 
circuits elicits parkinsonian motor symptoms with muscular dysfunctions, such as resting 
tremor, spontaneous dystonia, akinesia, sialorrhea, urinary dysfunction, and pain [10, 39]. 
While palliative therapies for PD subjects having sialorrler and urinary dysfunction using 
onabobotulinamtosinA (nealy equal to A1NTX) are going in bedside [12], there is currently a 
lack of curative therapies using ANTXs.
Several studies demonstrated that the intrastriatal injection of A1NTX reduces pathologic 
behavior in the rat 6-hydroxydopamine (6-OHDA)-induced Parkinson’s disease model (rat 
6-OHDA PD model) [11, 40]. These studies demonstrate the feasibility of clinical A1NTX 
application to treat PD without adverse side effects such as memory dysfunction [11, 40]. 
However, it is not clear which A1NTX has the greatest efficacy for treatment of PD. Therefore, 
we first compared the effect of A1NTX with that of A2NTX on pathogenic rotation behavior 
and in vivo cleavage of striatal SNAP-25 in the 6-OHDA PD rat model.
As a result, intrastriatal treatment of 6-OHDA-lesioned rats with A1NTX or A2NTX signifi-
cantly reduced the pathogenic rotation behavior in a dose-dependent manner (Figure 4). The 
highest tested dose of A1NTX (1 ng) conferred significant reduction of pathogenic behavior, 
as did all tested A2NTX doses (0.1, 0.5, and 1 ng). These results suggest that A2NTX has more 
potent inhibition of ACh release in the striatum than that of A1NTX [40]. Indeed, intrastria-
tal injection of the 6-OHDA-lesioned rats with A1NTX or A2NTX caused a dose-dependent 
Figure 4. Effects of intrastriatal injection of A1NTX (0.1, 0.5, or 1 ng/rat; n = 6 per dose), A2NTX (0.1, 0.5, or 1 ng/rat; 
n = 6 per dose), or vehicle (n = 7) on methamphetamine-induced rotation behavior. All rats received ANTX or vehicle 
injected into the lesioned striatum induced by 6-OHDA injection. For the tests, pre (white columns) represents before 
injection of ANTX, and post (black columns) represents after injection of ANTX. Data represent means ±S.E.M.; statistical 
significance is determined as pre versus post in a paired Student’s t-test; *p < 0.05; **p < 0.01. These data are cited from 
biochemical and biophysical research communications (Itakura et al., Vol;. 447(2), [2014] pp. 312 with the permissions 
from ELSEVIER).
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decrease in the level of full-length SNAP-25 in the striatum [40]. These results support the 
observed effects of A1NTX and A2NTX on rotation behavior (Figure 4). Additionally, we 
investigated the localization of cleaved SNAP-25 and choline acetyltransferase in the ANTX-
treated striatum by performing fluorescent immunocytochemical analysis [40]. These results 
indicate that A2NTX has greater efficacy for SNAP-25 cleavage in striatal terminals than 
that of A1NTX. Therefore, their dose-dependent efficacies in the striatum appear to differ, 
although the therapeutic effects of both toxin species on reducing pathologic rotation behav-
ior in a PD rat model are likely due to their cleavage of SNAP-25 [40].
Several side effects have been reported after therapeutic treatment with ANTXs for cervi-
cal dystonia and cosmetic cases, such as dysphagia and respiratory compromise [28, 29]. 
Our studies also demonstrated that the effects of botulinum toxin could spread from the 
injection site to other areas of the body causing symptoms similar to those of botulism [41]; 
A1NTX, but not A2NTX, was transported via axons to the contralateral side after injection 
into the foreleg muscles as described in Section 3. These results suggest that A2NTX may 
have a wider safety margin than that of A1NTX for therapeutic applications for PD. Thus, 
we investigated side effects after intrastriatal injection of either A1NTX or A2NTX in the rat 
6-OHDA PD model [42].
To investigate the distribution of A1NTX or A2NTX in the striatum, an immunofluorescent 
analysis of the cleaved SNAP-25, which is produced by ANTXs, is performed. The area of sur-
vey is shown in Figure 5A. Compared to the treatment with vehicle control (Figure 5B), the 
treatment with A1NTX increased the cleaved SNAP-25 in both the ipsilateral and contralateral 
striata (Figure 5C and E). In contrast, for A2NTX, the cleaved SNAP-25 signals were observed 
only in the ipsilateral striatum (Figure 5D and F). These results indicated that A2NTX was 
retained at the injection site, whereas A1NTX was diffused into the contralateral striatum.
Indeed, the previous study showed that ANTXs were retrogradely transported by central 
neurons and motoneurons and were then transcytosed to afferent synapses. The SNAP-25 
cleaved by ANTXs was observed in the contralateral hemisphere after unilateral ANTX injec-
tion to the hippocampus [12, 43]. Moreover, this finding is supported by our findings showing 
that A1NTX injected into the foreleg muscles was transported via axons to the contralateral 
side more readily than A2NTX as indicated in Section 3.
Furthermore, we evaluated changes in body weight as an index of the adverse effects of 
ANTX application. Body weights were measured 1 and 9 days after the 1.0 ng ANTX injec-
tion. Treatment with A1NTX resulted in significant loss of body weight compared to both the 
vehicle and A2NTX groups (Figure 6). Together with Figures 3 and 5, these results suggest 
the possibility that A1NTX, but not A2NTX, diffuses into the contralateral hemisphere lead-
ing to dysfunction in food/water intake.
Why does the difference between A1NTX and A2NTX arise in a rat PD model? Interestingly, 
A2NTX enters neuronal cells faster than A1NTX [44]. Additionally, we found that A1NTX 
and A2NTX have distinctly different distributions in the peripheral neuromuscular system 
in Section 3. Unfortunately, these findings only are not sufficient to explain the differences of 
ANTX subtypes in vivo. Thus, further studies are needed to elucidate the variation among 
ANTXs from the views of genetic, immunological, and neurological aspects.
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Figure 5. Distribution of A1NTX and A2NTX in the striatum. In (A), green squares represent the brain regions analyzed 
for the following experiments. Immunofluorescent analysis of cleaved SNAP-25 in the striatum following the intrastriatal 
injection of vehicle (n = 3) (B), ANTX1 (0.1, 0.5, 1.0 ng/rat; n = 3 per dose) (C) and A2NTX (0.1, 0.5, 1.0 ng/rat; n = 3 per 
dose) (D) are shown. Semiquantification of the cleaved SNAP-25 signals are shown for the contralateral (indicated as “c”) 
or ipsilateral (indicated as “i,” injected side) striatum relative to the vehicle-treated group (E and F). scale bars = 50 μm. 
Data represent means ± S.E.M.; statistical significance was determined as contralateral versus ipsilateral using a paired 
Student’s t-test; *p < 0.05, **p < 0.01. These data are cited from Journal of Veterinary Medical Science (Itakura et al., Vol. 
76(8), [2014] p. 1191 with the permissions from The Japanese).
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Figure 6. Loss of body weight induced by A1NTX injection. At one and 9 days after vehicle (n = 5), 1.0 ng A1NTX (n = 5) 
or 1.0 ng A2NTX (n = 4) injection, body weights were measured for all groups. Data represent means ± SE; statistical 
significance is determined as ANTX-treated groups versus vehicle using a Student’s t-test; **p < 0.01. These data are 
cited from Journal of Veterinary Medical Science (Itakura et al., Vol. 76(8), [2014] p. 1191 with the permissions from The 
Japanese Society Veterinary Science).
5. Conclusion
Considering the available evidence, it can be concluded that (1) the isolates associated with infant 
botulism were epidemiologically divided into NTXA gene cluster types. And, A1NTX and A2NTX 
have marked a difference in antigenicity. (2) A2NTX caused less muscle flaccidity of nontoxin-
treated muscle than A1 toxins. The variation in the amino acid sequence between A1NTX and 
A2NTX causes the difference in the spreading pathways. (3) A2NTX provides anti-PD effectiveness 
more effectively and confers greater safety than those of A1NTX. These findings might open a new 
therapeutic avenue for not only PD subjects but be useful also for application to other parkinonisms.
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6-OHDA 6-hydroxydopamineACh acetylcholine
ANTX Clostridium botulinum neurotoxin subtype A
Botulinum Toxin58
CNS central nervous system
A1NTX ANTX subtype A1
A2NTX ANTX subtype A2
GPS gelatin phosphate buffer (pH 6.2)
HA hemagglutinin component
KD values the affinity constant calculated as dissociation (kd) rate constant/associa-
tion (ka) rate constant
LD50 50% lethal dose
mAb monoclonal antibody
OD optical densities
Orfx unknown function open reading frame gene
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SNAP-25 synaptosomal-associated protein of 25 kDa
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